We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOOK
76
DELISTED
HOOKIPA Pharma
HOOK
$3.89M 0.02%
442,554
+95,000
+27% +$1.05M
EWTX icon
77
Edgewise Therapeutics
EWTX
$4.36B
$3.88M 0.02%
500,000
– –
GRCL
78
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.81M 0.02%
+1,000,000
New +$2.8M
CYPH
79
Cypherpunk Technologies Inc
CYPH
$65.4M
$3.67M 0.02%
1,172,175
+429,618
+58% +$2.16M
TLIS
80
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$3.66M 0.02%
508,322
– –
IPSC icon
81
Century Therapeutics
IPSC
$373M
$3.63M 0.02%
1,149,340
– –
MRSN
82
DELISTED
Mersana Therapeutics
MRSN
$3.57M 0.02%
43,445
-32,000
-42% -$4.68M
BCEL
83
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.46M 0.02%
3,532,760
– –
NGNE icon
84
Neurogene
NGNE
$675M
$3.17M 0.02%
191,087
– –
DSGN icon
85
Design Therapeutics
DSGN
$764M
$3.15M 0.02%
500,000
-126,884
-20% -$776K
XNCR icon
86
Xencor
XNCR
$1.48B
$3.07M 0.02%
123,127
– –
TIL icon
87
Instil Bio
TIL
$48.9M
$2.91M 0.02%
263,689
– –
TNGX icon
88
Tango Therapeutics
TNGX
$4.32B
$2.49M 0.01%
750,000
– –
PCVX icon
89
Vaxcyte
PCVX
$7.7B
$2.44M 0.01%
48,885
– –
ACHL
90
DELISTED
Achilles Therapeutics
ACHL
$2.42M 0.01%
2,557,149
-34,217
-1% -$32.5K
VERA icon
91
Vera Therapeutics
VERA
$2.4B
$2.35M 0.01%
146,464
-186,869
-56% -$1.69M
PRAX icon
92
Praxis Precision Medicines
PRAX
$8.28B
$2.16M 0.01%
125,328
– –
ALGS icon
93
Aligos Therapeutics
ALGS
$26.9M
$2.02M 0.01%
83,056
– –
PMVP icon
94
PMV Pharmaceuticals
PMVP
$57.1M
$2.02M 0.01%
322,024
– –
ITOS
95
DELISTED
iTeos Therapeutics
ITOS
$1.99M 0.01%
150,346
– –
VOR icon
96
Vor Biopharma
VOR
$1.09B
$1.96M 0.01%
31,692
– –
KALA icon
97
KALA BIO
KALA
$12.5M
$1.7M 0.01%
2,324
+788
+51% +$612K
CATX icon
98
Perspective Therapeutics
CATX
$331M
$1.55M 0.01%
+231,929
New +$1.41M
SYRE icon
99
Spyre Therapeutics
SYRE
$8.75B
$1.54M 0.01%
136,404
– –
KYNB
100
Kyntra Bio
KYNB
$27.9M
$643K ﹤0.01%
9,523
-95,972
-91% -$39.7M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Baker Bros. Advisors held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Baker Bros. Advisors added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Baker Bros. Advisors's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Baker Bros. Advisors fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Baker Bros. Advisors opened 6 new positions and closed 5 in Q2 2023.
  • Baker Bros. Advisors's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.